Clinical Trial Update: FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression [Phase 3]

View source ↗

Summary

A Phase 3 trial named FIBRONEER-ACT is evaluating nerandomilast for fibrosing interstitial lung disease at risk for progression. The study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosing Interstitial Lung Disease
• Interstitial Lung Disease

Drugs mentioned

• Nerandomilast

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Interstitial Lung Diseases | Phase 3 | Status: NOT_YET_RECRUITING